Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Early trial data has been very promising, and that's why interest is so high
Unfortunately, there is a small minority of patients, but that may be 20% of patients, that have untoward reactions to the Rifampin class
Furthermore, long-term redox disturbances and interactions with endogenous antioxidant systems are often under-evaluated
Long-term safety: As of April 2026, no long-term safety data exist for the injectable GLOW blend
US$ 24.63
US$ 23.86
US$ 21.74
US$ 20.57
US$ 27.97
US$ 21.56
US$ 27.21
